Finalized Dutch conditional reimbursement system imminent
This article was originally published in Scrip
Formal criteria for what a Dutch conditional reimbursement system will finally look like are due to emerge at the end of the year, Nefarma, the Dutch pharmaceutical industry association says. However, delays in having a finalized system in place could be advantageous to companies with products that are at higher risk of losing reimbursement, said the association.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.